FDA Grants Fast Track to Pelareorep for Anal Cancer, Third GI Designation
ONCY sits 19% above its 52-week low of $0.77.
Summary
The FDA granted Fast Track designation to pelareorep for second-line and later anal cancer, a $1B market with no approved therapies. This is the third Fast Track in gastrointestinal cancers, following colorectal and pancreatic, building regulatory momentum. The designation follows positive FDA alignment in April on a registrational path and is supported by GOBLET study data showing a 30% response rate—double historical benchmarks—and a 15.5-month median duration of response. With a clear pivotal trial framework and rapid site activation in the colorectal study, Oncolytics is advancing toward registration in high-value indications. The news de-risks the program and strengthens the case for pelareorep's potential, though the company's going concern and dilutive ATM sales remain financial overhangs.
At the time of this announcement, ONCY was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.8M. The 52-week trading range was $0.77 to $1.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.